Moody's could up Talecris

Moody's Investors Service said it placed Talecris Biotherapeutics, Inc.'s Caa1 corporate family and probability-of-default ratings under review for upgrade based on the signing of a new plasma supply agreement with CSL.

The issuer also has a Caa1 rating (LGD3, 45%) on its first-lien term loan and Caa2 rating (LGD5, 80%) for its second-lien term loan.

The agency said the signing of a separate plasma supply agreement with CSL through 2013 should help stabilize plasma levels and could have positive effects over the near term.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.